3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
11
Recruiting
5
Unknown
4
Terminated
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Peritoneal Neoplasms
2
Stomach Neoplasms
1
Ovarian Neoplasms
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Appendiceal Neoplasms
1
Adrenocortical Carcinoma
1
Interventions
pembrolizumab
24
Carboplatin
21
Paclitaxel
20
olaparib
19
Magnetic Resonance Spectroscopy
14
Bevacizumab
14
Cyclophosphamide
12
Specimen Handling
11
Nivolumab
11
Gemcitabine
11
Taxes
10
niraparib
8
Cisplatin
8
Biopsy
8
liposomal doxorubicin
7
fludarabine
7
Surveys and Questionnaires
6
Immunoglobulin G
6
Doxorubicin
6
Disulfides
6
durvalumab
5
palbociclib
4
oregovomab
4
X-Rays
4
Ipilimumab
4
mirvetuximab soravtansine
3
ipatasertib
3
defactinib
3
cediranib
3
atezolizumab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Ovarian Neoplasms
×
Cytoreduction Surgical Procedures
×
Clear all
NCT02124421
2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2
Active not recruiting
32 enrolled